Innovent Biologics (IVBXF) announced that China’s National Medical Products Administration has approved a New Drug Application of Dovbleron, a next-generation ROS1 tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have been previously treated with ROS1 TKIs.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IVBXF:
- Innovent Biologics Expands Portfolio with New Drug Approval
- Innovent Biologics Incentivizes Employees with Share Options
- Innovent Biologics Secures New Approval for Cancer Treatment
- Innovent Biologics’ Drugs Added to China’s Reimbursement List
- Innovent Biologics Ends Proposed Subscription Agreement
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
